APLS JPM 2026 Presentation_for website.pdf

1、ARCHERLiving with C3G44th Annual J.P.Morgan Healthcare ConferenceCedric Francois,M.D.,Ph.D.Co-Founder,Chief Executive Officer and PresidentJanuary 12,20262Statements in this presentation about future expectations,plans and prospects,as well as any other statements regarding matters that are not hist

2、orical facts,may constitute“forward-looking statements”within the meaning of The Private Securities Litigation Reform Act of 1995.The words“anticipate,”“believe,”“continue,”“could,”“estimate,”“expect,”“intend,”“may,”“plan,”“potential,”“predict,”“project,”“should,”“target,”“will,”“would”and similar e

3、xpressions are intended to identify forward-looking statements,although not all forward-looking statements contain these identifying words.Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,including adjustments to Ap

4、ellis preliminary revenue figures resulting from,among other things,the completion of financial closing and audit procedures for the quarter and year ended December 31,2025;whether the results of the Companys clinical trials for EMPAVELI,SYFOVRE,or any of its future products will warrant regulatory

5、submissions to the FDA or equivalent foreign regulatory agencies and whether the Company will make regulatory submissions when anticipated;whether systemic pegcetacoplan will receive approval from foreign regulatory agencies for C3G and primary IC-MPGN;the rate and degree of market acceptance and cl

6、inical utility of EMPAVELI,SYFOVRE and any future products for which we receive marketing approval will impact our commercialization efforts;whether data from the Companys clinical trials will be available when anticipated;whether results obtained in clinical trials will be indicative of results tha